Real-world effectiveness and safety of Ocrelizumab in a gulf multiple sclerosis cohort: extension of the Q-OCRE study to 451 patients. (PubMed, Mult Scler Relat Disord) - Oct 11, 2026 - "Infusion-related reactions occurred in 18.4%, adjudicated opportunistic infections in 1.0%, IgG below 7 g/L in 6.9%, and incident malignancy in 0.4%, with no deaths and no progressive multifocal leukoencephalopathy. Ocrelizumab showed robust effectiveness and a favorable safety profile in this Gulf cohort, with disability trajectories dissociating by phenotype."
Journal • Real-world evidence • CNS Disorders • Infectious Disease • Multiple Sclerosis • Oncology • Rare Diseases
|
|
Abdullah Althani; Alghalya Alemadi; Beatriz Garcia-Canibano; Doaa Hassanein; Fatme Mallat; Fayza Ahmed; Isra Eltazi; Khaled Zammar; Majd A AbuAlrob; Mohamed Sayed Abdelmoneim; Randa Yasin; Rola Khodair; Sami Alshehab; Shahd Hamid; Yahya Baniamer
|